Quantcast
Last updated on April 17, 2014 at 13:45 EDT

Latest Bioethics Stories

2013-12-23 23:03:30

A live version of Evidence in Motion’s Called to Care course will be facilitated by Dr. Larry Benz, Carmen Maria Romero, and Izetta Slade beginning January 20, 2014. Louisville, KY (PRWEB) December 23, 2013 Evidence In Motion (EIM) is thrilled to announce that Dr. Larry Benz, PT, DPT, OCS, MAPP, and CEO of PT Development (PTD), will be facilitating a live version of EIM’s recently released Called to Care course January 20th – February 28th, 2014. Carmen Maria Romero, PT, and Izetta...

2013-12-23 08:26:55

- Did not meet primary endpoint as measured by CT scan but trial demonstrated statistically significant reduction in lipoma surface area in responder analysis as determined by caliper- LYNBROOK, N.Y., Dec. 23, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced top-line data from Chien-804, the...

2013-12-23 08:26:06

PETACH TIKVA, Israel, Dec. 23, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist. The study entailed 2 arms, a placebo and a CF101 1...

2013-12-11 08:31:07

--Ongoing CUPID 2 Study Potential to Serve as Primary Basis of Efficacy and Safety Required for MMA Submission in European Union-- SAN DIEGO, Dec. 11, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that the Company has received requested scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the...

2013-12-09 08:28:41

- Findings Show Positive Trends in Slowing Advancement of Disease, as well as Enhanced Activity of NP001 in Patients with Increased Baseline Inflammation - PALO ALTO, Calif., Dec. 9, 2013 /PRNewswire/ -- Neuraltus Pharmaceuticals, Inc. announced today that promising efficacy results of the Company's Phase 2 clinical program of NP001 for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) were highlighted in an oral presentation at the 24th International...

2013-12-05 20:22:00

LEXINGTON, Massachusetts, December 5, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, today announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution. OPUS-2 compared lifitegrast to placebo administered twice daily for 84 days (12 weeks) in dry eye patients with history of active artificial tear use within 30 days prior to screening. Lifitegrast met the...

2013-11-26 16:25:02

WASHINGTON, Nov. 26, 2013 /PRNewswire-USNewswire/ -- Jon O'Brien, president of Catholics for Choice, released the following statement about Pope Francis' Apostolic Exhortation, Evangelii Gaudiam. "Pope Francis reassured Catholics today that some groundbreaking reforms in the church are on the way. The reform of the curia, the emphasis on economic justice and moves toward improving interfaith relations will receive considerable support from the laity. "When it comes to women, we...

2013-11-21 08:27:05

PRINCETON, N.J., Nov. 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it signed a stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC) providing an initial investment in Soligenix of $600,000 and...

2013-11-18 16:29:35

--Continued reduction in cardiovascular events and no safety concerns observed through three years of follow up in the MYDICAR high dose group-- SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that on behalf of the CUPID 1 Trial investigators, Dr. Barry H. Greenberg will present the full three year long-term follow up...

2013-11-14 23:26:48

Evidence In Motion releases Called To Care, a course that focuses on the non-clinical factors that impact patient outcomes. (PRWEB) November 14, 2013 Evidence In Motion (EIM) is pleased to announce the release of Called to Care, a program designed to shift healthcare away from deeply impersonal care towards an enhanced commitment among caretakers to high quality patient connections with an emphasis on compassion and empathy. Called to Care is based on recent research conducted by EIM...


Latest Bioethics Reference Libraries

OncoMouse
2013-10-02 09:29:43

The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...

More Articles (1 articles) »